U.S. market Closed. Opens in 15 hours 35 minutes

SYRE | Spyre Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue886.00K2.33M18.74MN/AN/A
Cost of Revenue964.00K1.96M2.00M1.62M901.00K
Gross Profit-78.00K365.00K16.74M-1.62M-901.00K
Operating Expenses129.45M87.11M84.39M81.48M79.43M
Selling, General & Admin39.95M28.53M27.32M21.84M14.83M
Research & Development89.50M58.58M57.07M59.64M64.60M
Other Operating Expenses-19.13M-7.00K-122.00K-5.00KN/A
Operating Income-242.30M-84.78M-65.65M-81.48M-80.33M
Other Expenses / Income-216.40M-7.00K-122.00K-5.00K2.08M
Before Tax Income-338.82M-83.95M-65.66M-80.89M-78.25M
Income Tax Expenses-26.00K-136.00K141.00K-593.00KN/A
Net Income-338.79M-83.81M-65.80M-80.89M-78.25M
Interest ExpensesN/AN/AN/AN/AN/A
Basic Shares Outstanding6.90M3.37M2.63M2.13M1.28M
Diluted Shares Outstanding6.90M3.37M2.63M2.13M1.28M
EBITDA69.45M-83.21M-64.07M-80.48M-79.43M
EBITDA Margin7,838.49%-3,572.95%-341.92%0.00%0.00%
EBIT-338.82M-83.95M-65.66M-81.49M-78.25M
EBIT Margin-38,241.08%-3,604.59%-350.39%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙